[Development of ABL tyrosine kinase inhibitors].
Kimura
Shinya
S
D000814:Aniline Compounds; D000970:Antineoplastic Agents; D001549:Benzamides; D000069439:Dasatinib; D015195:Drug Design; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D009570:Nitriles; D010879:Piperazines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D011804:Quinolines; D013844:Thiazoles
D000814:Aniline Compounds; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011804:Quinolines; D013844:Thiazoles; C406060:abl-bcr fusion protein, human; C471992:bosutinib; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib; C506918:bafetinib; D000069439:Dasatinib